OncRef
Skip to newsletter content
|
mCRPCFebruary 2026
0:00 / 3:22
Metastatic Castration Resistant Prostate Cancer — Monthly Compass
Feb 01–28, 2026 • Priority Updates • 3–5 minute read
 
A curated, practice-minded digest of what moved in metastatic castration resistant prostate cancer this month — regulatory signals, clinical development, and the most practice-relevant publications.
Built for oncologists OncRef Curated Oncology Intelligence Layer
metastatic castration resistant prostate cancer updates
Key Highlights
Key Highlights
  • Practice-Changing Updates
    • ASCO’s first Living Guideline for mCRPC endorses earlier lutetium‑177‑PSMA‑617 in PSMA‑positive disease and radium‑223 plus enzalutamide for select populations, providing sequencing clarity and driving earlier adoption.
  • Important Drug Publication Updates
    • Phase 3 PROpel patient‑reported outcomes show that olaparib plus abiraterone in first‑line mCRPC maintains health‑related quality of life and pain scores comparable to placebo plus abiraterone while delivering clinical benefit.
    • TALAPRO‑2 population pharmacokinetics demonstrate no clinically meaningful drug–drug interactions requiring dose modification when talazoparib is co‑administered with enzalutamide, with renal impairment impacting talazoparib clearance.
  • Key Clinical Development Updates
    • Johnson & Johnson reported Phase 1b pasritamig (JNJ‑78278343; KLK2×CD3) plus docetaxel data in mCRPC at ASCO GU 2026 and plans Phase 3 advancement, with pasritamig monotherapy already granted U.S. FDA Fast Track designation.
    • Clarity Pharmaceuticals’ SECuRE trial update described an mCRPC participant achieving undetectable PSA and negative PSMA PET and stated the SAR‑bisPSMA platform holds three FDA Fast Track designations as the company, following positive FDA interactions, plans a registrational Phase III.
  • Important Clinical Trial Publications
    • A validated first‑line mCRPC prognostic model integrating automated quantitative imaging of soft‑tissue and bone metastases with clinical and serum biomarkers significantly improved risk stratification versus serum‑only models.
  • Key Conference Updates
    • At ASCO GU 2026, real‑world evidence supported earlier use of lutetium‑177 PSMA‑617 before chemotherapy and dosimetry for Lu‑177 zadavotide guraxetan (PSMA‑I&T) projected low renal dose enabling expansion from four to six 7.4‑GBq cycles.
    • Alpha‑emitter and engager programs showed momentum with 225Ac‑PSMA‑Trillium achieving ≥80% PSA50 at the expansion dose and the pasritamig plus docetaxel combination yielding deep PSA responses with safety consistent with docetaxel alone.
  • Emerging Themes & Macro-Trends
    • PSMA‑directed radiotherapeutics are shifting earlier in the mCRPC pathway with optimized dosing paradigms, while alpha‑PSMA agents aim to redefine post‑177Lu salvage and pre‑chemotherapy intensification strategies.
    • Developers are prioritizing PSMA imaging access, dosimetry‑guided protocols, and community‑feasible administration models to scale radiotherapeutic and T‑cell engager adoption.
FDA Approvals/Withdrawals
FDA Approvals/Withdrawals
  • There are no press releases between 2026-02-01 and 2026-02-28 about metastatic castration resistant prostate cancer.
Clinical Development Regulatory Updates
Clinical Development Regulatory Updates
  • Johnson & Johnson reported Phase 1b data at ASCO GU 2026 for pasritamig (JNJ-78278343; KLK2×CD3 T‑cell engager) plus docetaxel in mCRPC and noted plans to advance to Phase 3; the company reiterated that pasritamig monotherapy has U.S. FDA Fast Track designation supporting continued development.¹ (read more)
  • Clarity Pharmaceuticals announced a SECuRE trial update in mCRPC showing a participant achieved undetectable PSA and negative PSMA PET; the company emphasized it holds three FDA Fast Track Designations for its SAR‑bisPSMA platform and cited positive interactions with the FDA as it plans a registrational Phase III trial.² (read more)
Conference
Major Conference Updates
Conference Information
  • 2026 ASCO Genitourinary Cancers Symposium; Moscone Center, San Francisco, CA; February 26–28, 2026. (read more)
  • Overall sentiment: Momentum is building around PSMA‑directed radiotherapeutics—now moving earlier with dosing optimization—and first clinical signals from alpha‑emitters and T‑cell engagers suggest the next efficacy wave in mCRPC. (read more)
  • Theme 1: Earlier, Optimized PSMA Radioligand Therapy (Lu‑177)
    • Significance: Real‑world evidence supports earlier use of Pluvicto (lutetium [177Lu] vipivotide tetraxetan) before chemotherapy, aligning treatment with disease biology and patient attrition realities. (read more)
    • Mechanism insights / clinical impact: Beta‑emitting PSMA ligands demonstrate durable benefit; ECLIPSE dosimetry for Lu‑177 zadavotide guraxetan (PSMA‑I&T) shows low projected renal dose, enabling protocol expansion from four to six 7.4‑GBq cycles—potentially extending disease control without added organ toxicity. (read more)
    • Patient populations affected: PSMA‑positive, ARPI‑exposed, chemotherapy‑naïve mCRPC (Pluvicto); ARPI‑progressing mCRPC enrolled in ECLIPSE. (read more)
  • Theme 2: Alpha‑Emitter PSMA Therapies Gain Traction
    • Significance: Early‑phase data for 225Ac‑PSMA‑Trillium (BAY 3563254) reported ≥80% PSA50 at the expansion dose, signaling potent activity and supporting advancement to the next phase; Lead‑212 (212Pb) ADVC001 TheraPb Phase 2 design highlights adaptive, dose‑intense strategies across key mCRPC settings. (read more)
    • Mechanism insights / clinical impact: Targeted alpha therapy concentrates high‑LET radiation over short path lengths; 212Pb’s 10.6‑hour half‑life underpins intensified induction with potential maintenance, aiming to maximize tumor kill while managing exposure. (read more)
    • Patient populations affected: Advanced mCRPC (including post‑177Lu‑PSMA) and pre‑chemotherapy mCRPC cohorts prioritized in emerging alpha‑therapy programs. (read more)
  • Theme 3: Bispecific T‑Cell Engagers Move Into Combinations
    • Significance: Pasritamig (JNJ‑78278343), a first‑in‑class CD3×KLK2 T‑cell engager, shows deep PSA responses with a safety profile consistent with docetaxel alone when combined—reviving immunotherapy potential in prostate cancer. (read more)
    • Mechanism insights / clinical impact: Tumor‑specific KLK2 targeting may focus immune activation on prostate tissue; combination data and office‑based administration profile suggest scalable community adoption if efficacy matures. (read more)
    • Patient populations affected: mCRPC patients eligible for docetaxel; early clinical experience spans “advanced prostate cancer,” with abstracts at ASCO GU specifying mCRPC. (read more)
  • Significance
    • Expected clinical or translational readouts: Pivotal ECLIPSE continues with six‑cycle schema; 225Ac‑PSMA‑Trillium slated for next‑phase development; pasritamig combination program advancing toward Phase 3. (read more)
    • Regulatory or policy implications: ASCO’s first Living Guideline for mCRPC endorses earlier lutetium‑177‑PSMA‑617 in PSMA‑positive disease and radium‑223 plus enzalutamide for select populations—accelerating adoption and sequencing clarity. (read more)
    • Potential shifts in standard of care: Earlier RLT use may entrench PSMA imaging–guided pathways; alpha‑PSMA agents could redefine post‑177Lu salvage and intensification strategies; T‑cell engager combinations may expand systemic options beyond ARPI/chemotherapy. (read more)
    • Strategic implications: Sponsors should invest in PSMA testing access, dosimetry‑guided protocols, and community‑feasible administration models to win share as radiotherapeutics and T‑cell engagers scale. (read more)
Publications Related to Approved Drugs
Phase 3
olaparib
Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study. Results from the Phase 3 PROpel trial demonstrate that adding olaparib to abiraterone in the first-line setting for mCRPC provides clinical benefit while maintaining health-related quality of life and pain scores comparable to placebo plus abiraterone. These findings suggest that the combination therapy does not negatively impact patient-reported outcomes despite the addition of a PARP inhibitor to the standard of care. ()
Phase 3
abiraterone acetate
Automated Imaging as an Adjunct to Serum and Clinical Biomarkers: A New Validated Prediction Tool for Metastatic Castration-Resistant Prostate Cancer. This study validated a new prognostic model for first-line mCRPC that integrates automated quantitative imaging of soft-tissue and bone disease with standard clinical and serum biomarkers. The inclusion of imaging data was found to significantly improve patient risk stratification compared to models relying solely on serum biomarkers, offering a more precise method for early outcome prediction in clinical trials. ()
Phase 3
talazoparib
Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer. A population pharmacokinetic analysis from the TALAPRO-2 study confirms that co-administration of talazoparib and enzalutamide in mCRPC patients does not result in clinically significant drug-drug interactions requiring dose modification. The model characterized the impact of renal impairment on talazoparib clearance but indicated that enzalutamide dose reductions do not necessitate changes to talazoparib dosing. ()
New Publications Related to Drugs in Clinical Trial Development
Phase 3
Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs. This publication outlines the rationale and design of two Phase 3 trials, OMAHA-003 and OMAHA-004, evaluating the novel steroidogenesis inhibitor opevesostat versus an androgen receptor pathway inhibitor (ARPI) switch in previously treated metastatic castration-resistant prostate cancer (mCRPC). The study addresses the critical need for therapies targeting androgen receptor ligand-binding domain mutations that drive resistance to current hormonal treatments, potentially positioning opevesostat as a new standard of care. (, )
Phase 2
WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide. The WOMBAT trial investigates the use of Bipolar Androgen Therapy (BAT) to resensitize tumors to darolutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who are experiencing biochemical progression. This strategy aims to delay the onset of metastatic disease and extend the utility of darolutamide by leveraging high-dose testosterone cycles to disrupt adaptive resistance mechanisms. ()
Phase 2
Efficacy of the ATR inhibitor ceralasertib in patients with ARID1A-deficient gynecologic and other solid tumor malignancies. This Phase 2 study assesses the ATR inhibitor ceralasertib in patients with ARID1A-deficient solid tumors, demonstrating a confirmed objective response rate of 14% across the cohort, with notable activity in gynecologic cancers. The findings support the concept of synthetic lethality in ARID1A-deficient tumors and highlight the potential for ATR inhibitors to modulate the tumor immune microenvironment in advanced solid malignancies. ()
Clinical Trials
Clinical Trials Summary
Number of Clinical Trials in metastatic castration resistant prostate cancer updated from 2026-02-01 to 2026-02-28:
Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Total
Enrolling by Invitation-------
Not Yet Recruiting111---3
Recruiting19148110-52
Available-------
Approved for Marketing-------
Active, Not Recruiting749-7229
Completed-------
Total271918117284
Phase 1 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Opevesostat, Dexamethasone, Fludrocortisone, Hydrocortisone NCT06136598 ACTIVE_NOT_RECRUITING A Phase 1 Clinical Study to Investigate the Safety and Pharmacokinetics of MK-5684 in China Participants With Metastatic Castration-Resistant Prostate Cancer 2026-03-10
Opevesostat, Dexamethasone, Fludrocortisone acetate, Hydrocortisone NCT06104449 ACTIVE_NOT_RECRUITING A Phase 1 Clinical Study to Investigate the Safety and Pharmacokinetics of MK-5684 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) 2026-04-12
Phase 2 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Abemaciclib, Atezolizumab NCT04751929 ACTIVE_NOT_RECRUITING A Phase II Multi-Center Trial of Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer 2026-04-30
Phase 3 Clinical Trials within 3 Months of Primary Completion Date:
No phase 3 trials completing within the next three months.
Phase 4 Clinical Trials within 3 Months of Primary Completion Date:
No phase 4 trials completing within the next three months.
NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.